Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

COVID-19 Monoclonal Antibody Therapeutics

October 11, 2021 -  State/territory-coordinated   Distribution of Monoclonal Antibody   Therapeutics. Learn More.
New and Notable: COVID-19 mAbs Announcements

View All

COVID-19 monoclonal antibody therapeutics (mAb) can be used to treat eligible non-hospitalized patients who have tested positive for COVID-19 and have mild to moderate symptoms. These treatments mimic your immune system’s response to SARS-CoV-2 (the infection that causes COVID-19) and are available to eligible patients 12 years and older with a high risk of progressing to severe forms of COVID-19 or being hospitalized. REGEN-COV can be administered through IV or subcutaneous injection.

HHS/ASPR has purchased supplies of COVID-19 mAb products and we are working with state and territorial health departments as well as national healthcare and medical organizations and associations to get the treatments into the hands of healthcare providers quickly, with a focus on areas of the country hardest hit by the pandemic.

The Federal Response: Clinical Implementation Guide The Clinical EvidenceWeekly update calls State/Territory-Coordinated Distribution

Resources for Professionals

Resources for Administration SitesResources for Healthcare and EMS Professionals Communications ToolkitPromising Practices for Healthcare Professionals 

  COVID-19 Therapeutics Frequently Asked Questions


Products Purchased by the US Government

REGEN-COVBam/estSotrovimab Bamlanivimab


  • This page last reviewed: October 11, 2021